This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CONMED's Buffalo Filter Buyout Likely to be Accretive in 2020
by Zacks Equity Research
CONMED's (CNMD) comprehensive surgical smoke evacuation portfolio lends it a competitive edge in the industry.
Varian Medical's Eclipse Picked by Paul Scherrer Institute
by Zacks Equity Research
Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.
Here's Why You Should Hold Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.
Varian Medical ProBeam-Equipped Emory Center Opens in Georgia
by Zacks Equity Research
Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
by Zacks Equity Research
Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.
Here's Why You Should Invest in athenahealth (ATHN) Now
by Zacks Equity Research
A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
A strong international presence and strategic buyouts aid Varian Medical (VAR); margins pressed.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.
OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 37.50% and -4.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will OPKO Health (OPK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo Stock Plunges on Phase II Chronic Cough Study Failure
by Zacks Equity Research
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.
Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology
by Zacks Equity Research
With the rising need for AP and molecular oncology services in healthcare, we consider the acquisition of PhenoPath by Quest Diagnostics (DGX) to be well-timed and a strategic fit for its portfolio.
OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial
by Zacks Equity Research
OPKO Health's (OPK) consistent focus on enhancing the efficacy of its flagship RAYALDEE platform is likely to lend it a competitive edge in the MedTech space.
OPKO Health (OPK) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 42.86% and 1.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK): Moving Average Crossover Alert
by Zacks Equity Research
OPKO Health, Inc. (OPK) is looking like an interesting pick from a technical perspective
OPKO Health's RAYALDEE Gets Approval in Canada to Treat CKD
by Zacks Equity Research
OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.
Here's Why You Should Hold Onto Opko Health (OPK) Stock Now
by Zacks Equity Research
Opko Health's (OPK) strong focus in R&D bodes well. However, the company faces cutthroat competition in the niche space.
Options Traders Expect Huge Moves in OPKO Health (OPK) Stock
by Zacks Equity Research
Investors in OPKO Health (OPK) need to pay close attention to the stock based on moves in the options market lately.
Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat
by Zacks Equity Research
Opko Health (OPK) gains from solid pharmaceutical business in the first quarter of 2018.
Implied Volatility Surging for Opko Health (OPK) Stock Options
by Zacks Equity Research
Surging implied volatility makes Opko Health (OPK) lucrative to the option traders.
OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.